These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 25739703)

  • 1. Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations.
    Maes H; Delforge M
    Expert Rev Hematol; 2015 Jun; 8(3):355-66. PubMed ID: 25739703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elderly patients with multiple myeloma: towards a frailty approach?
    Zweegman S; Engelhardt M; Larocca A;
    Curr Opin Oncol; 2017 Sep; 29(5):315-321. PubMed ID: 28763310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?
    Palumbo A; Mateos MV; Bringhen S; San Miguel JF
    Blood Rev; 2011 Jul; 25(4):181-91. PubMed ID: 21497966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal management of elderly patients with myeloma.
    Cerrato C; Mina R; Palumbo A
    Expert Rev Anticancer Ther; 2014 Feb; 14(2):217-28. PubMed ID: 24308685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of multiple myeloma in older adults: Gaining ground with geriatric assessment.
    Wildes TM; Campagnaro E
    J Geriatr Oncol; 2017 Jan; 8(1):1-7. PubMed ID: 27118356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
    Richardson P; Jagannath S; Colson K
    Clin Adv Hematol Oncol; 2006 May; 4(5):1; discussion 8; suppl 13. PubMed ID: 16830422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determining treatment intensity in elderly patients with multiple myeloma.
    Salvini M; D'Agostino M; Bonello F; Boccadoro M; Bringhen S
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):917-930. PubMed ID: 29972740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of older and frail patients with multiple myeloma in the Portuguese routine clinical practice: Deliberations and recommendations from an expert panel of hematologists.
    João C; Geraldes C; Neves M; Mariz M; Trigo F
    J Geriatr Oncol; 2020 Nov; 11(8):1210-1216. PubMed ID: 32601004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
    Delforge M; Bladé J; Dimopoulos MA; Facon T; Kropff M; Ludwig H; Palumbo A; Van Damme P; San-Miguel JF; Sonneveld P
    Lancet Oncol; 2010 Nov; 11(11):1086-95. PubMed ID: 20932799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple myeloma maintenance therapy: a review of the pharmacologic treatment.
    Shank BR; Brown VT; Schwartz RN
    J Oncol Pharm Pract; 2015 Feb; 21(1):36-51. PubMed ID: 24395544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of older patients with multiple myeloma.
    Gay F; Palumbo A
    Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.
    Palumbo A; Bringhen S; Mateos MV; Larocca A; Facon T; Kumar SK; Offidani M; McCarthy P; Evangelista A; Lonial S; Zweegman S; Musto P; Terpos E; Belch A; Hajek R; Ludwig H; Stewart AK; Moreau P; Anderson K; Einsele H; Durie BG; Dimopoulos MA; Landgren O; San Miguel JF; Richardson P; Sonneveld P; Rajkumar SV
    Blood; 2015 Mar; 125(13):2068-74. PubMed ID: 25628469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial treatment of nontransplant patients with multiple myeloma.
    Cerrato C; Palumbo A
    Semin Oncol; 2013 Oct; 40(5):577-84. PubMed ID: 24135402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
    Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P
    Oncology; 2006; 70(6):474-82. PubMed ID: 17283449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
    Kleber M; Ihorst G; Udi J; Koch B; Wäsch R; Engelhardt M
    Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):38-48. PubMed ID: 22054851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs in multiple myeloma.
    Ghobrial IM; Leleu X; Hatjiharissi E; Hideshima T; Mitsiades C; Schlossman R; Anderson KC; Richardson P
    Expert Opin Emerg Drugs; 2007 Mar; 12(1):155-63. PubMed ID: 17355220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
    Möller J; Nicklasson L; Murthy A
    J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.